AMC

in page functions

15 June 2015

Remaining AMC offer amount: June 2015

The official formal notification of the remaining AMC Offer Amount

22 April 2015

2015 Pneumococcal AMC Annual Report

The 2015 Pneumococcal AMC Annual Report gives an overview of the activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2014 to 31 March 2015.

28 January 2015

Pneumococcal AMC Inflation Review Application Process

The process for manufacturers interested in submitting an Inflation Review Application.

15 December 2014

Pneumococcal AMC OECD GDP Deflator Data

Pneumococcal AMC: OECD GDP Deflator Data Purpose: As per the Pneumococcal AMC Inflation Review Application Process, listed below is the OECD GDP Deflator to be used to calculate an inflation adjustment request. BASE QTR Q2-2009 Q2-2010 Q2-2011 Q2-2012 Q2-2013 Q2-2014 Q2-2015 Q2-2016 Q2-2017 Q2-2018 Q2-2019 Q2-2020 Q2-2

13 June 2014

Remaining AMC offer amount: June 2014

As of 12 June 2014, the Remaining AMC Offer Amount, corresponding to the AMC funds still available for allocation to industry, is: US $ 405,000,000.

01 May 2014

2014 Pneumococcal AMC Annual Report

This progress report presents an overview of the activities linked to the implementation of the pneumococcal AMC from 1 April 2013 to 31 March 2014. It was developed by the AMC Secretariat at GAVI, in collaboration with the World Bank and UNICEF’s Supply Division, and was approved by the Independent Assessment Committee on 1 May 2014.

24 April 2014

IAC Members

List of IAC members.

28 March 2014

Pneumo Strategic Demand Forecast - Version 8_0

Published 28 March 2014 PNEUMOCOCCAL CONJUGATE VACCINE Strategic Demand Forecast Version 8.0. This version 8.0 is issued in accordance with the GAVI Forecasting Standard Operating Procedure.

28 June 2013

Remaining AMC offer amount: June 2013

Remaining AMC offer amount: June 2013

29 April 2013

2013 Pneumococcal AMC Annual Report

The 2013 Pneumococcal AMC Annual Report gives an overview of the activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2012 to 31 March 2013. During this period a third tender was issued in response to the high level of country demand and eight countries introduced pneumococcal vaccines procured through the AMC, taking the total to 24 introductions by March 2013.

09 August 2012

Pneumo Strategic Demand Forecast - Version 5_0 – Published 13 August 2012

ACCELERATE VACCINE INTRODUCTION – PNEUMOCOCCAL CONJUGATE VACCINE Strategic Demand Forecast (Required Supply) Version 5.0 – updated in March 2012 Published – 13 August 2012 This version 5.0 is issued in accordance with the AVI Forecasting Standard Operating Procedure.

19 June 2012

Remaining AMC offer amount: June 2012

Remaining AMC offer amount: June 2012

01 June 2012

2012 Pneumococcal AMC Annual Report

The 2012 Pneumococcal AMC Annual Report gives an overview of all activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2011 to 31 March 2012. It provides an extensive description of the first achievements of this innovative initiative: the first introductions of pneumococcal vaccines in GAVI countries.

22 August 2011

Manufacturers FAQs

Frequently asked questions about Advance Market Commitments for vaccines for manufacturers.

16 June 2011

Remaining AMC offer amount: June 2011

The official formal notification of the remaining AMC Offer Amount.

01 April 2011

2011 Pneumococcal AMC Annual Report

The 2011 Pneumococcal AMC Annual Report gives an overview of all activities linked to the implementation of the pilot Advance Market Commitment from 1 April 2010 to 31 March 2011.

11 March 2011

Pneumo SDF version 3.0 – published on 11 March 2011

This version 3.0 is issued in accordance with the AVI Forecasting Standard Operating Procedure. The forecast captures all AMC‐eligible demand including countries that: introduce with GAVI support, graduate from GAVI support, and are fully self-financed.

09 March 2011

AMC Legal Agreements: detailed list of modifications

List of modifications to the AMC legal agreements.

07 March 2011

AMC deed of amendment and restatement

AMC deed of amendment and restatement relating to the Advance Market Commitment for pneumococcal vaccines offer agreement, IAC Charter & bylaws and procedures memorandum orginally dated 12 June 2009.

07 March 2011

Revised AMC procedures memorandum

This Procedures Memorandum describes the procedures that would be applicable to any AMC.

07 March 2011

Revised AMC offer agreement

 

Offer agreement relating to the Advance Market Commitment for pneumococcal vaccines.

29 October 2010

AMC Baseline Study

The AMC Baseline Study presents an innovative new approach to public health funding as a way of stimulating and accelerating the development and manufacture of vaccines for developing countries.

01 September 2010

Serotype Replacement Note - Prepared by the IAC

The serotype replacement issue arises from extensive use of pneumococcal conjugate vaccine, which is expected to result in some increase of disease occurence due to serotypes not in the vaccine. This raises question whether the increases could reach a point where the benefit of the vaccine is lost, or the increases will be small relative to the decline in vaccine type disease.

23 August 2010

AMC IAC eligibility determination meeting: 23 August 2010

The purpose of the meeting was to review Pfizer’s application for AMC eligibility for Prevenar 13 and determine if the candidate vaccine met the TPP for the AMC.

16 June 2010

Remaining AMC offer amount 2010

The official formal notification of the remaining AMC Offer Amount.

16 April 2010

Minutes from AMC Eligibility Determination Meeting April 2010

Minutes from AMC Eligibility Determination Meeting held in London, UK on 16 April 2010.

16 April 2010

PneumoADIP

PneumoADIP is a small, dedicated team based at Johns Hopkins Bloomberg School of Public Health, supported by a $30 million grant from the GAVI Alliance.

31 March 2010

2010 Pneumococcal AMC Annual Report

This progress report presents an overview of the activities linked to the implementation of the pneumococcal AMC since the signature of the legal agreements on 12 June 2009 up until 31 March 2010. It was developed by the AMC Secretariat at GAVI, in collaboration with the World Bank and UNICEF’s Supply Division, and was approved by the Independent Assessment Committee on 13 April 2010.

12 November 2009

IAC Members 2009

List of IAC members.

27 October 2009

IAC Selection Process

The selection process for Independent Assessment Committee (IAC) members is administered by the GAVI Alliance Secretariat, in its role as AMC Secretariat. Evaluation of candidates is conducted by a selection panel composed of five international leaders on global health issues.

01 October 2009

Case Studies for Global Health - The World’s First Advance Market Commitment

A case study on the multi-sector effort to build a financing mechanism, the AMC, as an incentive to facilitate vaccine development.

02 September 2009

The Pneumococcal AMC - the Process

The process of the Pneumococcal AMC involves donors, IBRD, UNICEF, suppliers, the AMC Independent Assessment Committee (IAC), developing countries and participating manufacturers.

07 August 2009

Pneumo SDF version 0.1 – published on 7 August 2009

This version 0.1 is issued in accordance with the AVI Forecasting Standard Operating Procedure that foresees the possibility for intermediate updates between official versions when changes in demand exceed predefined thresholds. 

03 July 2009

Master Definitions Agreement

Master definitions schedule relating to the AMC for pneumococcal vaccines.

03 July 2009

Questions and answers about the AMC (FAQs)

Frequently asked questions about the Pneumococcal AMC.

03 July 2009

Questions and answers about the AMC (FAQs) [Français]

Frequently asked questions about the Pneumococcal AMC.

 

12 June 2009

Pneumo SDF version 0 – published on 12 June 2009

Pneumococcal vaccine strategic demand forecast corresponding to AMC required supply.

20 April 2009

Consultation and Advisory Process

The World Bank, The GAVI Alliance and the AMC Donor Committee sought stakeholder input on the planning and design of the pilot AMC through expert groups, consultations, meetings and roundtables. The aim was to incorporate into the design of the AMC the recommendations of economists, global health experts, medical practitioners and scientists from developing and industrialized countries as well as manufacturers and civil society organizations. 

11 March 2009

Revised Independent Assessment Committee charter and bylaws

The charter and bylaws of the Independent Assessment Committee (IAC).

01 March 2009

The Pneumococcal AMC - the Process [Français]

The process of the Pneumococcal AMC involves donors, IBRD, UNICEF, suppliers, the AMC Independent Assessment Committee (IAC), developing countries and participating manufacturers.

18 December 2008

TPP Master Table

The master table of the target product profile (TPP), product specifications, relate to the public health impact and suitability of the product. 

18 December 2008

TPP Supplementary Information

Supplementary informational for the target product profile (TPP) including general information, vaccine characteristics relevant to the TPP, contributors and WHO policy documents. 

11 December 2008

Minutes from December 2008 meeting

Minutes from the AMC Independent Assessment Committee (IAC) meeting on 11 December 2008.

30 November 2008

TPP Codebook

Codebook to assess whether a pneumococcal vaccine meets the Pneumococcal AMC Target Product Profile for regional vaccine serotype coverage.

13 November 2008

Monitoring and Evaluability Study

The report was commissioned by the Monitoring & Evaluation Subgroup of the AMC Donor Committee in August 2007. The monitoring and evaluation proposals contained in this report have been designed to enable the effectiveness, efficiency and eventual impact of this pilot AMC to be measured over time and to assist with its effective management.

03 November 2008

Minutes from November 2008 meeting

Minutes from the AMC Independent Assessment Committee (IAC) meeting on 3 November 2008.

10 July 2008

Implementation Working Group (IWG) Report

This report presents the group’s operational recommendations to inform donors’ decisions on AMC design and implementation. It is intended as an addendum to the EEG report, rather than a stand-alone document; therefore, readers will find a number of cross-references.

10 July 2008

IWG Joint Donor Statement

 In February 2007, a collective US$1.5 billion for a pilot Advance Market Commitment (AMC) against pneumococcal disease was pledged by the Governments of Italy, the UK, Canada, Russia and Norway, and the Bill & Melinda Gates Foundation. The report recommends the terms on which the AMC will be offered to help developing countries buy new, more effective pneumococcal vaccines.

01 April 2008

Economic Expert Group (EEG) Report

A report prepared by the Economic Expert Group convened by the GAVI Alliance to provide guidance to the pneumococcal AMC donors about key design decisions using new information available from industry consultations, demand forecasts and modeling of returns to industry under various demand and price scenarios.

17 March 2008

All-Party Parlimentary Group on Pneumococcal Disease Report

This report summarises the results of the All-Party Parliamentary Group for Pneumococcal Disease Prevention in the Developing World (APPG) inquiry into pneumococcal disease in the developing world.

29 June 2007

Independent Expert Committee Recommendation for AMC Pilot

The Independent Expert Committee was convened to assess which of the six vaccines included in the Tremonti report would be most suitable for the pilot AMC.

11 March 2007

EEG Donor response

In May 2007, the AMC Donor Committee constituted an independent Economic Expert Group (EEG) to advise on the initial AMC design. This document is the donors' response to the EEG report.

09 February 2007

IFPMA Press Release in support of AMC Launch

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) welcomes the public commitment made by the governments of Canada, Italy, Norway and the United Kingdom to fund the pilot Advance Market Commitment (AMC) to stimulate the development of new pneumococcal vaccines for the poorest countries.

09 February 2007

Remarks by Her Majesty Queen Rania of Jordan on the AMC Launch 2007

Remarks of Her Majesty Queen Rania Al-Abdullah on the announcement of Advanced Market Commitments of $1.5 billion in Rome, Italy on 9 February 2007.

09 February 2007

Bill and Melinda Gates Foundation - Statement of Support

Statement from the Bill and Melinda Gates foundation announcing support for the pneumococcal AMC.

09 February 2007

Pope Address at Vaccine Project Launch

The address Pope Benedict XVI gave to the representatives of the Advance Market Commitment in Rome, Italy on 9 February 2007.

08 February 2007

Pneumococcal Disease - The Human Face

Stories of three young children in Africa and Asia and their fight against pneumococcal disease.

08 February 2007

Pneumococcal Disease Background

Streptococcus pneumoniae are bacteria that are frequently found in the upper respiratory tract of healthy children and adults. These bacteria, however, can also cause a range of infections – from relatively mild ear infections to fatal pneumonia, meningitis, and sepsis. Serious pneumococcal infections can occur throughout life, but children under two years old and the elderly are at highest risk. 

09 November 2006

Second Donor Working Group - Framework

Framework document for the pilot AMC for pneumococcal vaccines.

09 November 2006

Second Donor Working Group - Participants London, November 2006

List of participants at the 2nd meeting of the AMC working group.

09 November 2006

Second Donor Working Group - Agenda London, November 2006

Agenda of the second meeting of the Technical Working Group in London on 9 November 2006.

09 November 2006

Second Donor Working Group - Summary London, November 2006

Summary of the second meeting of the Technical Working Group on AMC held in London on 9 November 2006.

07 September 2006

First Donor Working Group - Summary Rome, 7 September 2006

Summary of the first meeting of the Technical Working Group on AMC held in Rome on 7 September 2006.

07 September 2006

Pilot Proposal

Pilot proposal for the Advance Market Committment to demonstrate both the feasability of the AMC mechanism and its impact on accelerating vaccine development, production scale-up and introduction.

28 February 2006

Independent Expert Committee Membership

List of members of the Indepedent Expert Committee meeting in Paris, France held the 27-28 February 2008.

02 December 2005

Tremonti Report to the G8 Finance Ministers

Background papers to the AMC providing the analysis underpinning Minister Giulio Tremonti's Report to the G8 Finance Ministers Advanced Market Commitments to Vaccines.

11 March 2005

Making markets for vaccines: Ideas to action

This report discusses the need to invest more in vaccines and the proposal of making a commitment in advance to buy vaccines if and when they are developed to create incentives for industry to increase investment in research and development.

 



close icon

modal window here